- Home
- FMST vs APLM Comparison
FMST vs APLM Comparison
Compare FMST & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- APLM
- Stock Information
- Founded
- FMST 2005
- APLM 2016
- Country
- FMST Canada
- APLM United States
- Employees
- FMST N/A
- APLM N/A
- Industry
- FMST Other Metals and Minerals
- APLM Blank Checks
- Sector
- FMST Basic Materials
- APLM Finance
- Exchange
- FMST Nasdaq
- APLM Nasdaq
- Market Cap
- FMST 15.8M
- APLM 15.6M
- IPO Year
- FMST N/A
- APLM N/A
- Fundamental
- Price
- FMST $1.60
- APLM $9.75
- Analyst Decision
- FMST
- APLM Strong Buy
- Analyst Count
- FMST 0
- APLM 2
- Target Price
- FMST N/A
- APLM $425.00
- AVG Volume (30 Days)
- FMST 34.3K
- APLM 107.4K
- Earning Date
- FMST 01-01-0001
- APLM 02-15-2025
- Dividend Yield
- FMST N/A
- APLM N/A
- EPS Growth
- FMST N/A
- APLM N/A
- EPS
- FMST N/A
- APLM N/A
- Revenue
- FMST N/A
- APLM $2,101,000.00
- Revenue This Year
- FMST N/A
- APLM N/A
- Revenue Next Year
- FMST N/A
- APLM N/A
- P/E Ratio
- FMST N/A
- APLM N/A
- Revenue Growth
- FMST N/A
- APLM 70.54
- 52 Week Low
- FMST $1.32
- APLM $6.50
- 52 Week High
- FMST $3.50
- APLM $105.00
- Technical
- Relative Strength Index (RSI)
- FMST 46.69
- APLM 50.39
- Support Level
- FMST $1.43
- APLM $7.23
- Resistance Level
- FMST $1.77
- APLM $8.88
- Average True Range (ATR)
- FMST 0.20
- APLM 1.37
- MACD
- FMST 0.05
- APLM 0.21
- Stochastic Oscillator
- FMST 61.76
- APLM 57.91
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.